Lurbinectedin has shown noteworthy clinical activity in metastatic breast cancer with mutations in BRCA 1/2
Lurbinectedin ( Zepsyre ) has shown noteworthy clinical activity in patients with metastatic breast cancer that have mutations in the BRCA 1 and/or BRCA 2 genes.
A phase II trial has assessed the c ...
read article